胸部序贯放疗较巩固放疗延长广泛期小细胞肺癌无进展生存期

发布时间：2019-03-21 07:13

【摘要】：目的比较胸部序贯放疗与巩固放疗在广泛期小细胞肺癌(ED-SCLC)的意义。方法收集2010年1月至2013年6月期间接受胸部放疗的ED-SCLC患者102例。运用Kaplan-Meier法对序贯胸部放疗和巩固放疗的2组患者的无进展生存(PFS)及总生存(OS)进行生存分析。结果序贯放疗组中位PFS、1年PFS率依次为11.0月、39.6%,巩固放疗组依次为9.4月、7.7%(P=0.000)。序贯放疗组中位、1年、2年OS率依次为15.0月、77.7%、4.6%;巩固放疗组依次为14.2月、82.4%、2.4%(P=0.58)。单因素分析发现PS评分=0分,化疗3程及序贯放疗改善PFS。多因素分析发现化疗3程及序贯放疗是影响PFS的两个独立预后因子。亚组分析发现无论化疗≤3程还是3程,序贯放疗组PFS皆延长。结论胸部序贯放疗可延长部分高选择性ED-SCLC患者的PFS。化疗疗程3程和序贯放疗是其两个独立预后因素。
[Abstract]:Objective to compare the significance of sequential chest radiotherapy and consolidation radiotherapy in patients with extensive small cell lung cancer (ED-SCLC). Methods 102 ED-SCLC patients received thoracic radiotherapy from January 2010 to June 2013 were collected. The survival rates of progression-free survival (PFS) and total survival (OS) of two groups of patients undergoing sequential thoracic radiotherapy and consolidation radiotherapy were analyzed by Kaplan-Meier method. Results the median 1-year PFS rate of PFS, in sequential radiotherapy group was 11.0 months, 39.6%, and that in consolidation radiotherapy group was 9.4 months and 7.7%, respectively (P < 0.05). The median OS rate in the sequential radiotherapy group was 15.0 months, 77.7%, 4.6% at 1 year and 2 years, and 14.2 months, 82.4%, 2.4% in the consolidation radiotherapy group (P < 0.05), and that in the consolidation radiotherapy group was 14.2 months, 82.4% and 2.4% (P < 0.05), respectively. Univariate analysis showed that PS score = 0, 3-course chemotherapy and sequential radiotherapy improved PFS.. Multivariate analysis showed that three-course chemotherapy and sequential radiotherapy were two independent prognostic factors for PFS. Subgroup analysis showed that the PFS of sequential radiotherapy group was prolonged regardless of chemotherapy 鈮，

本文编号：2444708